ELWT Investor News: If You Have Suffered Losses in Elauwit Connection, Inc. (NASDAQ: ELWT), You Are Encouraged to Contact The Rosen Law Firm...

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

All-Round for Work & Play: KTC Dual-Mode Monitor H27P6 Adapts to Full-Scenario Needs

Global Aerospace's SM4 Aviation Safety Program Offers Essentials on Sleep Need vs. Sleep Capacity and The Science of Sleep Banking

LCID SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Lucid Group, Inc. Investors - Contact Kirby McInerney LLP by July 28,...

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. (WGS)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors it Has Filed a Complaint to Recover Losses Suffered by Purchasers of Verra...

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two...

DentaQuest Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care...

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific...

"I'm Fine - a Lie Lived. A Childhood Survived. A Story Told - On My Terms," by Gina Gee

Chisos Releases a New Run of the Only Bench-Made Cowboy Boot Built from Wild Texas Alligator

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining...

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes-...

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600